EB1089 Induces Skp2-Dependent p27 Accumulation, Leading to Cell Growth Inhibition and Cell Cycle G1 Phase Arrest in Human Hepatoma Cells

REFERENCES

• Hansen C. M., Hamberg K. J., Binderup E., Binderup L. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 2000; 6(7)803–828
   PubMed Web of Science ®Google Scholar
• Bernardi R. J., Johnson C. S., Modzelewski R. A., Trump D. L. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinol 2002; 143(7)2508–2514
   PubMed Web of Science ®Google Scholar
• Ordonez-Moran P., Larriba M. J., Pendas-Franco N., Aguilera O., Gonzalez-Sancho J. M., Munoz A., Vitamin D. and cancer: an update of in vitro and in vivo data. Front Biosci 2005; 10: 2723–2749
   PubMed Web of Science ®Google Scholar
• Fernandez-Garcia N. I., Palmer H. G., Garcia M., Gonzalez-Martin A., del Rio M., Barettino D., et al. 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene. 2005; 24(43)6533–6544
   PubMed Web of Science ®Google Scholar
• Hoyer-Hansen M., Bastholm L., Mathiasen I. S., Elling F., Jaattela M., Vitamin D. analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ 2005; 12(10)1297–1309
   PubMed Web of Science ®Google Scholar
• Chen T. C., Holick M. F., Lokeshwar B. L., Burnstein K. L., Schwartz G. G. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 2003; 164: 273–288
   PubMedGoogle Scholar
• Takahashi H., Ibe M., Kinouchi M., Ishida-Yamamoto A., Hashimoto Y., Iizuka H. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003; 31(1)21–28
   PubMed Web of Science ®Google Scholar
• Stio M., Bonanomi A. G., d'Albasio G., Treves C. Suppressive effect of 1,25-dihydroxyvitamin D3 and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis. Biochem Pharmacol 2001; 61(3)365–371
   PubMed Web of Science ®Google Scholar
• Milliken E. L., Zhang X., Flask C., Duerk J. L., MacDonald P. N., Keri R. A. EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Lett 2005; 229(2)205–215
   PubMed Web of Science ®Google Scholar
• Valrance M. E., Welsh J. Breast cancer cell regulation by high-dose Vitamin D compounds in the absence of nuclear vitamin D receptor. J. Steroid Biochem. Mol Biol 2004; 89–90(1–5)221–225
   PubMed Web of Science ®Google Scholar
• Pagano M., Tam S. W., Theodoras A. M., Beer-Romero P., Del Sal G., Chau V., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269(5224)682–685
   PubMed Web of Science ®Google Scholar
• Chen T. P., Chen C. M., Chang H. W., Wang J. S., Chang W. C., Hsu S. I., et al. Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms. Gynecol Oncol 2007; 104(3)516–523
   PubMed Web of Science ®Google Scholar
• Wang C., Hou X., Mohapatra S., Ma Y., Cress W. D., Pledger W. J., et al. Activation of p27Kip1 Expression by E2F1. A negative feedback mechanism. J Biol Chem 2005; 280(13)12339–12343
   PubMed Web of Science ®Google Scholar
• Huang C., Ma W., Ding M., Bowden G. T., Dong Z. Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase. J Biol Chem 1997; 272(44)27753–27757
   PubMed Web of Science ®Google Scholar
• Ouyang W., Ma Q., Li J., Zhang D., Liu Z. G., Rustgi A. K., et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res 2005; 65(20)9287–9293
   PubMed Web of Science ®Google Scholar
• Blain S. W., Scher H. I., Cordon-Cardo C., Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003; 3(2)111–115
   PubMed Web of Science ®Google Scholar
• Carrano A. C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Bio 1999; 1(4)193–199
   PubMed Web of Science ®Google Scholar
• Sutterluty H., Chatelain E., Marti A., et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biol 1999; 1(4)207–214
   PubMed Web of Science ®Google Scholar
• Wang Q. M., Jones J. B., Studzinski G. P. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996; 56(2)264–267
   PubMed Web of Science ®Google Scholar
• Li P., Li C., Zhao X., Zhang X., Nicosia S. V., Bai W. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem 2004; 279(24)25260–25267
   PubMed Web of Science ®Google Scholar
• Flynn G., Chung I., Yu W. D., Romano M., Modzelewski R. A., Johnson C. S., et al. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncol 2006; 70(6)447–457
   Google Scholar
• Gedlicka C., Hager G., Weissenbock M., Gedlicka W., Knerer B., Kornfehl J., et al. 1,25(OH)2Vitamin D3 induces elevated expression of the cell cycle inhibitor p18 in a squamous cell carcinoma cell line of the head and neck. J Oral Pathol Med 2006; 35(8)472–478
   PubMed Web of Science ®Google Scholar
• Alagbala A. A., Johnson C. S., Trump D. L., Posner G. H., Foster B. A. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2–2) in squamous cell carcinoma cells. Oncol 2006; 70(6)483–492
   Google Scholar
• Lin R., Wang T. T., Miller W. H., Jr., White J. H. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. Endocrinol 2003; 144(3)749–753
   PubMed Web of Science ®Google Scholar
• Malumbres M., Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nature Rev 2001; 1(3)222–231
   Web of Science ®Google Scholar
• Fero M. L., Randel E., Gurley K. E., Roberts J. M., Kemp C. J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998; 396(6707)177–180
   PubMed Web of Science ®Google Scholar
• Baldassarre G., Belletti B., Bruni P., Boccia A., Trapasso F., Pentimalli F., et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 1999; 104(7)865–874
   PubMed Web of Science ®Google Scholar
• Kullmann M., Gopfert U., Siewe B., Hengst L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′ UTR. Genes & Dev 2002; 16(23)3087–3099
   PubMed Web of Science ®Google Scholar
• Pumiglia K. M., Decker S. J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proceedings of the National Academy of Sciences of the United States of America 1997; 94(2)448–452
   PubMed Web of Science ®Google Scholar
• Spruck C., Strohmaier H., Watson M., Smith A. P., Ryan A., Krek T. W., et al. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Molecular Cell 2001; 7(3)639–650
   PubMed Web of Science ®Google Scholar
• Tsvetkov L. M., Yeh K. H., Lee S. J., Sun H., Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol Jun 17, 1999; 9(12)661–664
   PubMed Web of Science ®Google Scholar
• Gstaiger M., Jordan R., Lim M., Catzavelos C., Mestan J., Slingerland J., et al. Skp2 is oncogenic and overexpressed in human cancers. Proceedings of the National Academy of Sciences of the United States of America 2001; 98(9)5043–5048
   PubMed Web of Science ®Google Scholar
• Kudo Y., Kitajima S., Sato S., Miyauchi M., Ogawa I., Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001; 61(19)7044–7047
   PubMed Web of Science ®Google Scholar
• Lu L., Schulz H., Wolf D. A. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Bio 2002; 20(3)22
   Google Scholar
• Latres E., Chiarle R., Schulman B. A., Pavletich N. P., Pellicer A., Inghirami G., et al. Role of the F-box protein Skp2 in lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America 2001; 98(5)2515–2520
   PubMed Web of Science ®Google Scholar